Colorectal Cancer Screening by Gaskie, Sean
 
 
FPIN's Clinical Inquiries 
Clinical Inquiries provides answers to questions submitted by practicing family physicians to the 
Family Practice Inquiries Network (FPIN). Members of the network select questions based on 
their relevance to family medicine. Answers are drawn from an approved set of evidence-based 
resources and undergo peer review. The strength of recommendations and the level of evidence 
for individual studies are rated using criteria developed by the Evidence-Based Medicine 
Working Group (http://www.cebm.net/levels_of_evidence.asp). 
This series of Clinical Inquiries is coordinated for American Family Physician by John Epling, 
M.D., State University of New York Upstate Medical University, Syracuse, N.Y. The complete 
database of evidence-based questions and answers is copyrighted by FPIN. If you are interested 
in submitting questions to be answered or writing answers for this series, go to 
http://www.fpin.org or contact CI2Editor@fpin.org. 
Colorectal Cancer Screening 
Clinical Question 
To screen for colorectal cancer, is annual fecal occult blood testing (FOBT) just as good as 
flexible sigmoidoscopy? 
Evidence-Based Answer 
Yes. Both FOBT and flexible sigmoidoscopy are effective in screening for colorectal cancer. 
FOBT can reduce mortality from colorectal cancer. [Strength of recommendation: A, based on 
high-quality systematic reviews of randomized controlled trials (RCTs)] Flexible sigmoidoscopy 
has a higher diagnostic yield, but its effect on colorectal cancer mortality has been less rigorously 
demonstrated. [Strength of recommendation: B, based on high-quality systematic reviews of 
well-designed case-control studies] 
Evidence Summary 
A recent systematic review1 of high-quality RCTs for the U.S. Preventive Services Task Force 
(USPSTF) found a disease-specific mortality reduction of 15 to 21 percent over eight to 18 years 
with a regimen of biennial, non-rehydrated FOBT. The absolute risk reduction was 1.1 to 4.6 per 
1,000 person-years; if FOBT screening is offered to 10,000 persons and two thirds are tested at 
least once, approximately eight deaths from colorectal cancer can be prevented over 10 years. 
Subsequent reports show that these mortality reductions persist.2,3 These outcomes were 
reported from intention-to-treat analyses, and were observed even though screening compliance 
was low (around 60 percent). Disease-specific mortality reductions were greater (around 30 
percent) for patients who were more compliant with screening. 
Sensitivity and specificity of a single-home FOBT are about 40 and 96 percent, respectively. 
Sensitivity improves when screening is performed regularly over several years. In the annual 
screening arm of the 13-year Minnesota trial,4 repeated annual screening found 92 percent of 
colorectal cancers. 
Good case-control studies of flexible sigmoidoscopy suggest a mortality reduction of 59 percent 
(95 percent confidence interval [CI], 31 to 75 percent) for cancers within reach of the scope. The 
benefit would be smaller when considering all cancers. However, there are no convincing RCTs 
(a study design less subject to bias than case-control studies) that demonstrate mortality 
reduction. One small, Norwegian RCT cited in the USPSTF review followed patients for 13 
years and reported a trend toward disease-specific mortality reduction in patients undergoing 
flexible sigmoidoscopy compared with patients who were not screened (relative risk: 0.50; 95 
percent CI, 0.10 to 2.72). Two large RCTs comparing flexible sigmoidoscopy (once-in-a-lifetime 
in the United Kingdom, every five years in the United States) against no screening will report 
their initial results within the next four years.1 Screening effectiveness and test characteristics for 
FOBT and flexible sigmoidoscopy are summarized in the accompanying table. 
Characteristics of Screening Tests for Colorectal Cancer in Average-Risk Adults 
 
  Screening strategy   
 
Category 
Fecal occult blood test 
(samples 
from three consecutive 
stools) 
 
Flexible sigmoidoscopy (one time) 
Effectiveness in 
reducing mortality 
from colorectal cancer 
Annual testing: colorectal 
cancer mortality reduction 
of 33% (95% CI, 7%, 49%) 
Biennial: colorectal cancer 
mortality 
reduction of 18 to 21% 
(95% CI, 
3%, 38%) 
Small RCT found non-significant trend 
toward reduced colorectal cancer mortality 
(RR: 0.50; 95% CI, 0.10, 2.72) 
Case-control studies suggest 59% (95% CI, 
31%, 75%) reduction in risk of colorectal 
cancer death for cancers within reach of 
scope 
Ability to detect 
cancers 
One-time sensitivity 30 to 
40% for 
colorectal cancer 
Less sensitive for polyps 
A program of repeated 
annual testing 
One-time screening detects 68 to 78% of 
advanced neoplasia (cancers and polyps 
that are large, villous, or dysplastic) found 
on complete colonoscopy 
can find 92% of cancers 
Likelihood of 
generating false-
positive results 
Positive predictive value 
for colorectal 
cancer: 5 to 15% 
85 to 90% false-positive 
results 
5 to 10% of patients will 
require 
colonoscopy over 10 years 
of testing 
- 
Adverse effects 
 
No direct adverse effects 
known 
Complication during 
follow-up 
colonoscopy (perforation or 
bleeding) 
in 1 of 2,000 procedures 
< 1 in 10,000 perforation rate for diagnostic 
examinations; bleeding after 2.5% of 
diagnostic studies, 5.5% of procedures with 
polypectomy 
 
C I = confidence interval; RCT = randomized controlled trial; RR = relative risk. 
Adapted with permission from Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening 
for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive 
Services Task Force. Ann Intern Med 2002;137:132-41. 
Recommendations from Others 
The U.S. Multi-society Task Force on Colorectal Cancer, convened by the Agency for 
Healthcare Research and Quality, recommends screening for colorectal cancer in all men and 
women 50 years of age and older (and younger for those persons with increased familial risk).5 
Screening options include annual FOBT, flexible sigmoidoscopy every five years, FOBT plus 
flexible sigmoidoscopy, barium enema, or colonoscopy every 10 years. The USPSTF, American 
Academy of Family Physicians, American Cancer Society, the major U.S. gastroenterology 
societies, and the Canadian Task Force on Preventive Health Care are participating in the 
development of the guidelines. 
Clinical Commentary 
What is the best test for colorectal cancer screening? When only considering tests that are 
performed routinely in the primary care office, FOBT and flexible sigmoidoscopy are 
comparable, although the mortality benefit of FOBT is better established. While the use of 
optical colonoscopy, virtual colonoscopy, or molecular-based fecal tests is outside the scope of 
this question, none has randomized controlled data with mortality as an outcome to support its 
use. It is important to remember that colorectal cancer is prevalent and preventable, but only a 
small number of Americans are being screened. Therefore, physicians should pick the screening 
tool they are most comfortable with and screen all patients as necessary. 
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